Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A | P35348 | 6/20 | 0.64 |
| ▸ | DRD3 | P35462 | 8/20 | 0.63 |
| ▸ | DRD2 | P14416 | 7/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | HTR1A | P08908 | 3/20 | 0.53 |
| ▸ | DRD4 | P21917 | 6/20 | 0.50 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.50 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.50 |
| ▸ | HTR2A | P28223 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13809558 | 0.90 | DRD3 (0.58) | ADRA1ADRD3DRD2ALDH1A1SMN1; SMN2 | |
| SCHEMBL7817697 | 0.89 | ADRA1A (0.73) | ADRA1ADRD3DRD2HTR1ADRD4 | |
| SCHEMBL13809559 | 0.85 | ADRA1A (0.69) | ADRA1ADRD3DRD2HTR1ADRD4 | |
| SCHEMBL13809546 | 0.85 | ADRA1A (0.69) | ADRA1ADRD3DRD2HTR1ADRD4 | |
| SCHEMBL13809551 | 0.84 | ADRA1A (0.68) | ADRA1ADRD3DRD2HTR1ADRD4 | |
| SCHEMBL13809541 | 0.84 | ADRA1A (0.67) | ADRA1ADRD3DRD2HTR1ADRD4 | |
| SCHEMBL13809587 | 0.82 | DRD2 (0.64) | ADRA1ADRD3DRD2HTR1ADRD4 | |
| SCHEMBL13809533 | 0.82 | ADRA1A (0.66) | ADRA1ADRD3DRD2HTR1ADRD4 | |
| SCHEMBL13809566 | 0.82 | ADRA1A (0.71) | ADRA1ADRD3DRD2HTR1ADRD4 | |
| SCHEMBL7824411 | 0.81 | ADRA1A (0.70) | ADRA1ADRD3DRD2HTR1ADRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7550469-B2 | Heterocyclic amide derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2009-06-23 | — | — | US | disclosed |
| US-20070142351-A1 | Novel heterocyclic amide derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2007-06-21 | — | — | US | disclosed |
| US-20070142351-A1 | Novel heterocyclic amide derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142351-A1 | Novel heterocyclic amide derivatives and their use as dopamine D3 receptor ligands | DRD3, DRD2, DRD1 | ADRA1A 313/4885DRD3 1/4885DRD2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.